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Material and Methods
Samples
Blood samples were taken from patients after consent and approvals from the ethical committee of Siriraj, Khon Kaen and Songkhla hospitals, Thailand. The study was also approved by the Riverside Ethics Committee in the UK. Acute DENV infection was identified by RT-PCR-based DENV gene identification or DENV-specific IgG and IgM capture ELISA (1, 2). Disease severity was classified according to the World Health Organization criteria (3) .
Of the patients enrolled in the study, 1 patient was classified as DF, 6 as DHF. Blood samples were collected in heparin (BD). PBMC were isolated from whole blood by Ficoll-Hypaque density gradient centrifugation and cryopreserved until tested. Characteristics of DENV-infected cases enrolled in the study are summarised in table S1.
Cells and Antibodies C6/36, a cell line derived from the mosquito Aedes albopictus was cultured in Leibovitz L-15 medium supplemented with 10% heat-inactivated foetal bovine serum (FBS), 0.26% tryptose phosphate broth (TPB), 100 units/ml penicillin, 100 µg/ml streptomycin and 2 mM L-Glutamine at 28ºC. For endotoxin-free conditions, cells were grown in the absence of TPB. Vero, a cell line derived from the kidney of African green monkeys and U937, a human monocytic cell line, were grown in MEM and RPMI1640, respectively. The media were supplemented with 10% FBS, 100 units/ml penicillin, 100 µg/ml streptomycin and 2 mM L-Glutamine in a 37ºC humidified 5% CO 2 incubator. Monocyte-derived dendritic cells (DC) were prepared as previously described (4) . LoVo cells were cultured in Nutrient mixture (Ham) F12 medium containing 20% FBS.
Conjugated antibodies against human or mouse Ig (DAKO) were used. Pooled convalescent dengue hyperimmune human serum (PCS) (hemagglutination titre ≥ 1/25600), pooled non-dengue immune serum (PND) (hemaggutination inhibition titre and anti-dengue Ab ELISA negative) and mouse anti-DENV envelope, 4G2, were kindly provided by AFRIMS, Thailand. NS1-F3, 2G6 and 1H10 are anti-NS1 and anti-prM mAb, respectively (5, 6) .
Virus stock
DENV serotype 1 (Hawaii), serotype 2 (16681), serotype 3 (H87) and serotype 4 (H241) were propagated in C6/36 cells and virus supernatant was collected and stored at -80ºC. The DENV stock propagated from C6/36 and MDDC's were free from endotoxin and mycoplasma detected by Limulus amebocyte lysate assay (Whittaker M.A.) and PCR using the mycoplasma detection set (TAKARA BIO INC), respectively. For poorly infectious DENV, C6/36 cells were infected with DENV2. Four days after infection, culture medium was replaced by fresh L-15 containing 1.5% FBS and 0.26% TPB with 10 or 20 mM NH 4 Cl for 2 hrs and the medium was then replaced again. At 24 hrs after the medium containing NH 4 Cl was added, virus particles were harvested and precipitated by 10% PEG 8000. Fully immature virus was produced on LoVo cells as previously described (7) . Briefly, virus was produced by infecting LoVo cells with DENV2 strain 16681 at MOI of 10 and virus was harvested at 2 days.
Focus forming assay
The titres of virus were determined by a focus forming assay on Vero cells and expressed as focus-forming units (FFU) per ml. Briefly, virus was serially diluted and incubated with Vero cells for 2 hrs at 37°C. The monolayers were then overlaid with 1.5% carboxymethylcellulose and incubated at 37°C for 3 days. Virus foci were stained with anti-E antibody (4G2) followed by peroxidase-conjugated anti-mouse Ig and visualized by the addition of DAB substrate.
Generation of dengue-specific human monoclonal Abs DENV-specific human mAb's were generated as previously described (8) . Briefly, IgG + memory B cells were positively selected from PBMC through magnetic sorting using MACS CD22 microbeads (Miltenyibiotec) followed by depletion of IgA, IgD and IgM expressing cells by FACS-sorting. Isolated IgG + memory B cells were then transformed with EBV and cultured in RPMI containing 10% FCS, 2.5 ug/ml CpG, 10 ng/ml, IL-2, 30 ug/ml holo-Transferrin and irradiated allogeneic PBMC. After 2 weeks, culture supernatants were screened for anti-DENV specific antibodies. Human EBV-transformed B cells producing anti-DENV antibodies were then cloned by limiting dilution. All human monoclonal antibodies used in this study are summarised in table S3.
Detection of dengue-specific human Abs by ELISA
Mixtures of all four DENV serotypes were captured onto a MAXISORP immunoplate (NUNC) coated with mouse anti-E antibody (4G2) or anti-NS1 antibody (NS1-F3). DENV captured wells were then incubated with B cell line (BCL) culture supernatants followed by alkaline phosphatase (AP)-conjugated anti-human IgG Abs. The reaction was visualized by the addition of PNPP substrate. The reaction was stopped with NaOH.
ELISA for prM:E ratio and the number of E molecules of poorly infectious DENV
To determine the prM:E ratio and to estimate the number of virus-equivalent particles, DENV was captured onto plates coated with anti-E antibody (4G2) and then detected with human anti-prM or E mAb. Recombinant E protein (a gift from Dr. Jonathan Grimes and Aleksandra Flanaga, University of Oxford, UK), produced in Sf9 cells was used to plot a standard curve to calculate the concentration of E. The relative concentration of prM was expressed as the OD ratio of prM:E measured by ELISA and the number of virus-equivalent particles estimated assuming each particle would contain 180 copies of the E protein.
Western blot and Dot blot analysis
For western blot analysis, lysates from dengue infected C6/36 cells treated with 1% triton X-100 in PBS were run on 12% SDS polyacryramide gels without heating under nonreducing conditions and electroblotted onto nitrocellulose membranes (Amersham). For dot enzyme immunoassay, culture supernatants from mock, DENV or JEV infected C6/36 cells were dotted onto nitrocellulose membranes. The membranes were then blocked with PBS containing 5% skimmed milk and probed with BCL supernatants or plasma samples diluted 1:100 followed by peroxidase-conjugated anti-human IgG Abs. Finally, membranes were developed with enhancement chemiluminescence substrate (Amersham).
Focus reduction neutralisation test (FRNT)
Neutralizing activity of DENV-specific Abs was determined by the focus reduction neutralisation test (FRNT) (9) . Briefly, serially diluted antibody was mixed with an equal volume of virus and incubated for 1 hr at 37°C. The mixtures were then transferred to Vero cell monolayers followed by the focus forming assay described above.
Antibody-dependent infection enhancement assay
Serially diluted antibody was incubated with an equal volume of virus for 1 hr at 37°C then transferred to U937 cells and incubated at 37°C for 4 days. Supernatants were then harvested and viral titre assessed by a focus forming assay as described above. Alternatively, after 24 hrs, U937 was fixed and permeabilised in 4% paraformaldehyde and 0.5% saponin. DENV antigens were then stained intracellularly with anti-DENV (4G2) followed by phycoerythrin-conjugated anti-mouse IgG Abs and analysed by flow cytometry.
In preliminary experiments, to check that intracellular staining with anti-E antibody-4G2 represented DENV infection we compared 4G2 staining with 2G6 an antibody to NS1 (Fig. S3D) . Staining of infected monocytes was similar, but as 4G2 showed a larger shift in staining (Fig. S3E) this was chosen for use in further assays.
DENV infected PBMC and FACS analysis
PBMC were infected with endotoxin-free DENV in the presence of different concentrations of antibodies for 24 hrs. Cells were then fixed, permeabilised, and stained for DENV antigen by intracellular staining as described above.
DENV immunoprecipitation
The supernatants from DENV2 infected culture were pre-cleared with protein A-agarose beads for 1 hr at 4 ºC. After centrifugation, supernatant was incubated with 10 μg of 4G2 for 2 hrs at 4 ºC. Protein A-agarose beads were then added and incubated for 1 hr at 4 ºC. After washing, proteins were eluted with non-reducing loading buffer and run on a 15% SDS-polyacrylamide gel followed by silver staining according to the manufacture protocol (SilverQuest staining kit, Invitrogen). Western blots of C6/36 cell lysates infected with DENV1-DENV4 and probed with primary immune DENV serum (A). Plasma diluted 1 in 100 from five cases each of DENV1, DENV2 and DENV3 were analysed by Western blot for anti-prM against the four DENV serotypes and reactivity was then scored (B) . Western blots were probed individually as single lane strips. Reactivity of the 6 anti-prM antibodies to reduced (R) and non-reduced (N) DENV infected cell lysates showing loss of reactivity on reduced Western blots (A). To show reactivity to the pr peptide, western blotting of culture supernatant (non-heat/nonreduced) from DENV (B) and mock (C) infected cells was preformed. Non reduced gels were run in loading buffer lacking 2-mercaptoethanol which were also non-heat treated. Western blots were probed individually as single lane strips. 1  2  1  10  2  3  0  3  2  2  0  12  17  1  2  14  3  2  1  22  8  2  1  15  4  unknown  0  26  9  8  0  18  5  1  1  28  6  9  0  12  6  4  0  0  2  1  3  12  7  2  0  2  0  1  0  1 *cross reacts between DENV and JEV ** no cross-reaction to JEV 
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